Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
Take Tell Us What YOU Think! Take The Body's Visitor Survey!
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Human Genome Sciences Inc. Says Study Showed Hepatitis-C Drug Showed Positive Results

From U.S. Centers for Disease Control and Prevention

April 19, 2005

On Thursday, Human Genome Sciences Inc. announced its experimental hepatitis C drug was well tolerated and reduced the virus in some treatment-naive patients. The study involved 56 patients who were each given one of five doses of Albuferon. Patients were given two doses of Albuferon 14 days apart and were followed for six weeks, with the rate of viral load assessed on the 28th day. Sixty-nine percent of the patients taking the two highest doses achieved the targeted viral load reduction on the 28th day of the study. Hepatitis C is the most common chronic blood-borne infection in the developed world and afflicts about 4 million people in the United States, the company said.

Back to other news for April 19, 2005

Adapted from:
Associated Press
04.14.05

  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
 

Advertisement